ABSTRACT
La hemoglobina reticulocitaria es un nuevo parámetro dentro de los autoanalizadores hematológicos de cuarta generación, siendo indispensable en el diagnóstico y manejo de eritropoyesis deficiente en hierro, especialmente la deficiencia funcional de hierro, el secuestro de hierro y la deficiencia absoluta de hierro. Además, este parámetro demuestra ser más preciso que las pruebas bioquímicas como el hierro sérico, la ferritina y la saturación de transferrina, en la detección precoz de eritropoyesis deficiente en hierro. El objetivo de la investigación fue describir la utilidad clínica de la hemoglobina reticulocitaria (CHr) en el diagnóstico temprano de eritropoyesis por deficiencia de hierro absoluto en mujeres adolescentes. El tipo de investigación fue descriptivo, analítico, el diseño de campo transversal. La muestra voluntaria, no aleatoria estuvo constituida por 62 mujeres adolescentes con edades comprendidas entre los 14 y 19 años. Como resultado se encontró que el 97% de la muestra tiene disminución de la CHr, indicando eritropoyesis deficiente en hierro, mientras que un 3% de las adolescentes presentan valores normales para la CHr, se realizó la relación diagnostica entre pruebas de laboratorio tales como CHr y el Hierro sérico. También se reportó que el 93% de la muestra presenta déficit de hierro sin anemia, y un 7% tiene anemia ferropénica, el rango de edad con mayor predominio de anemia ferropénica fue entre los 14 y 16 años. Se concluye que la CHr es de utilidad clínica y una nueva herramienta de diagnóstico temprano de eritropoyesis por deficiencia de hierro.
Reticulocyte hemoglobin is a new parameter within the fourth generation hematological autoanalyzers, being indispensable in the diagnosis and management of iron deficient erythropoiesis, especially functional iron deficiency, iron sequestration and absolute iron deficiency. Moreover, this parameter proves to be more accurate than biochemical tests such as serum iron, ferritin and transferrin saturation in the early detection of iron deficient erythropoiesis. The aim of the research was to describe the clinical utility of reticulocyte hemoglobin (CHr) in the early diagnosis of absolute iron deficiency erythropoiesis in adolescent females. The type of research was descriptive, analytical, cross-sectional field design. The voluntary, non-random sample consisted of 62 adolescent females aged between 14 and 19 years. As a result, it was found that 97% of the sample had decreased CHr, indicating iron deficient erythropoiesis, while 3% of the adolescents had normal values for CHr. The diagnostic relationship between laboratory tests such as CHr and serum iron was performed. It was also reported that 93% of the sample presented iron deficiency without anemia, and 7% had iron deficiency anemia; the age range with the highest prevalence of iron deficiency anemia was between 14 and 16 years of age. It is concluded that HRH is clinically useful and a new tool for early diagnosis of erythropoiesis due to iron deficiency.
A hemoglobina reticulócita é um novo parâmetro dentro da quarta geração de auto-analisadores hematológicos, sendo indispensável no diagnóstico e manejo da eritropoiese com deficiência de ferro, especialmente deficiência funcional de ferro, seqüestro de ferro e deficiência absoluta de ferro. Além disso, este parâmetro prova ser mais preciso do que testes bioquímicos como ferro sérico, ferritina e saturação da transferrina na detecção precoce de eritropoiese com deficiência de ferro. O objetivo da pesquisa foi descrever a utilidade clínica da hemoglobina reticulocitária (RCHr) no diagnóstico precoce da eritropoiese absoluta de deficiência de ferro em mulheres adolescentes. O tipo de pesquisa foi descritivo, analítico, de corte transversal do campo. A amostra voluntária e não aleatória consistiu de 62 fêmeas adolescentes com idades entre 14 e 19 anos. Como resultado, descobriu-se que 97% da amostra tinha uma diminuição na HRH, indicando uma eritropoiese com deficiência de ferro, enquanto 3% das adolescentes tinham valores normais para HRH. Também foi relatado que 93% da amostra tinha deficiência de ferro sem anemia, e 7% tinha anemia por deficiência de ferro; a faixa etária com maior prevalência de anemia por deficiência de ferro era entre 14 e 16 anos. Conclui-se que o RHH é clinicamente útil e uma nova ferramenta para o diagnóstico precoce da eritropoiese devido à deficiência de ferro.
Subject(s)
Anemia , Iron DeficienciesABSTRACT
Introducción. La anemia por deficiencia de hierro en hemodiálisis es frecuente. Para su detección se utiliza la ferritina sérica y la saturación de transferrina (ST). El equivalente de hemoglobina reticulocitaria (RET-He) es un análisis que no se modifica en estados inflamatorios y refleja directamente el hierro disponible en médula ósea.Objetivo. Explorar la capacidad diagnóstica de deficiencia absoluta de hierro del RET-He y evaluar su correlación con marcadores tradicionales de ferropenia.Población y métodos. Estudio retrospectivo que comparó RET-He con ferritina y ST en niños en hemodiálisis atendidos en el Hospital Garrahan entre julio de 2016 y julio de 2019. Resultados. En 164 observaciones realizadas en 40 niños, se encontró correlación positiva débil entre hemoglobina y RET-He (r 0,35, p < 0,001), positiva significativa entre ST y RET-He (r 0,52, p < 0,001), negativa baja entre hemoglobina y ferritina (r -0,19, p 0,02) y ausencia de correlación entre hemoglobina y ST (r 0,05, p 0,5). El 50 % presentaba anemia; la ferropénica fue por marcadores tradicionales en el 13 % y por RET-He en el 44 %. El RET-He mostró sensibilidad del 90,9 % (IC 95: 57,1-99,5 %), especificidad del 74,5 % (IC 95: 66,7-81 %), valor predictivo negativo del 99,1 % (IC 95: 94,5-99,9 %) y positivo del 20,4 % (IC 95: 10,7-34,7 %) para detectar anemia ferropénica con valor de corte de 29 picogramos.Conclusiones. Pese a su capacidad limitada, el RET-He como biomarcador de deficiencia de hierro aumenta la detección de anemia ferropénica en niños en hemodiálisis
Introduction. Iron-deficiency anemia is common in hemodialysis patients. Serum ferritin and transferrin saturation (TS) are used for its detection. The reticulocyte hemoglobin equivalent (RET-He) is a marker that is not altered by inflammatory conditions and directly reflects iron availability in the bone marrow.Objective. To explore the diagnostic capability of RET-He to detect absolute iron deficiency and assess its correlation with traditional markers of iron deficiency.Population and methods. Retrospective study comparing RET-He with ferritin and TS in children on hemodialysis seen at Hospital Garrahan between July 2016 and July 2019.Results. In 164 observations carried out in 40 children, a weak positive correlation was found between hemoglobin and RET-He (r = 0.35, p < 0.001), a significant positive correlation between TS and RET-He (r = 0.52, p < 0.001), a low negative correlation between hemoglobin and ferritin (r = -0.19, p = 0.02), and a lack of correlation between hemoglobin and TS (r = 0.05, p = 0.5). Anemia was observed in 50 %; iron-deficiency anemia was detected by traditional markers in 13 % and by RET-He in 44 %. RET-He showed a sensitivity of 90.9 % (95 % CI: 57.1-99.5 %), a specificity of 74.5 % (95 % CI: 66.7-81 %), a negative predictive value of 99.1 % (95 % CI: 94.5-99.9 %), and a positive predictive value of 20.4 % (95 % CI: 10.7-34.7 %) to detect iron-deficiency anemia with a cut-off value of 29 pg.Conclusions. Despite its limited capability, the use of RET-He as a biomarker of iron deficiency increases the detection of iron-deficiency anemia in children on hemodialysis.
Subject(s)
Humans , Male , Female , Infant, Newborn , Infant , Child, Preschool , Child , Adolescent , Renal Dialysis , Anemia, Iron-Deficiency/diagnosis , Reticulocytes/chemistry , Hemoglobins/analysis , Retrospective Studies , Ferritins/bloodABSTRACT
Background: Iron deficiency is the most common cause of anemia and studies have shown poor cognition, psychomotor and social/emotional development in children who are deficient in iron, even with normal hemoglobin levels, the so-called Latent phase of Iron deficiency. It is therefore crucial to identify LID, as well as IDA at the earliest stage, in order to initiate treatment.' Many tests like serum ferritin and soluble transferring receptor(sTfR) have been described collectively as a panel to detect iron deficiency; however no single test is specific enough to be used independently. Also during treatment it takes weeks to observe changes in Hb, hematocrit or RBC indices, hence the need for a more sensitive and reliable test. Objective was to evaluate effectiveness of CHr in diagnosing LID and IDA.Methods: Samples were collected from 180 children, clinically suspected to be anemic. Complete hemogram and Iron profile were measured. Three groups were defined, LID (Tfsat <20%, Hb >11g/dL; n=52), IDA (Tfsat <20%, Hb <11g/dL; (n=84) and controls (Tfsat >20%, Hb >11g/dL; n=44). The mean values of RBC indices, Iron profile and CHr was compared across the groups. A cut off value of <26 pg CHr was taken to represent Iron deficiency state.Results: Comparison between anemic group and control found that all RBC indices were found to be significantly lower including Reticulocyte hemoglobin. All of the variables in anemic group were lower compared to latent iron deficient group except MCHC and reticulocyte count. CHr was found to be statistically lower in LID and IDA group in comparison to control group.Conclusions: CHr can be used as a valuable indicator in diagnosis as well as follow-up of LID and IDA, which is easily available and inexpensive.
ABSTRACT
@#BACKGROUND. Regular blood donation can lead to pre-clinical iron deficiency as well as iron deficiency anemia. With Each donation donors lose 220-250 mg of iron. Early detection of iron deficiency is important for the blood donors and even useful for blood and blood product safety and supply. The research work we studied present Ret-HE to be used to detect the occurrence of iron deficiency eritrony level. Purpose: The aim of this study was to determine Ret-He to have sensitivity and specificity for diagnosing iron deficiency than traditional iron measurements. Materials and methods: We performed a cross sectional and case control study of 156 blood donors who served National Center for Transfusion Medicine. Ret-He, hemoglobin, plasma iron and ferritin were measured using XN2000 Sysmex, and CobasE600 Roche. The statistical analysis was done using One way Anova, Rock curve, Kruskal Wallis test. Results: We examined 64(41.02%) male donors, 92(58.9%) female donors by measurements of Ret-He,hemoglobin, serum, iron and ferritin. Survey participants were 8.33%(n=13) with anemia, 91.67% (n=143) without anemia. In donors with anemia the results were: RBC 4.9*106 u/l, HGB 10.8 g/dl (10;11), serum ferritin 5.2 (4.3; 6.3) mmol, serum iron 4.5 (3.7; 5.8) mmol and Ret-He 25.5 (22; 26) pg. Donors were divided into 3 age groups: group I age was up to 25years, group II was between 26-35 years, group III age criteria was above 35. Group I had serum iron 13.5 (10.; 18.), serum ferritin 41.8 (14; 78), Ret-He 32.2 (30; 33.) RBC 5×106 u/l (4.6;5), HGB14.2g/dl (13.3;14. 2). Group II had serum iron 14.6 (11; 19), serum ferritin 54.1 μg/l (29; 138), Ret-He 32.2pg (31; 33), RBC 5.1×106 u/l(4.7;5.1), HGB14.8 g/dl (13.5;14.8),Group III had serum iron 15.1 umol/l (9; 20), serum ferritin 95.7 μg/l (39; 141), Ret-He 32.7pg (31; 34) , RBC4.9×106 u/l(4.6;4.9), HGB 14.5g/dl(13.8;14.5), respectively. According to a curve (Roc) analysis, AUC of serum iron was 0.0963, serum ferritin 0.909, Ret-He 0.975. The mean Ret-He was 32.3pg (31.3;33.4). The optimal cut off value for the Ret-He was 29,25pg by ROC analysis and are presented along with sensitivity 92.3% and specificity 95.1%. Conclusion: 1. Determining the amount of Ret-He has a better sensitivity and specificity for diagnosing iron deficiency compared to traditional iron measurements. 2. Ret-He has diagnostic indicators that are able to detect the depletion of iron reserves, erythron level. And it need to be used in further clinical practices, as well as doctors should be required to use it for diagnosis and treatment.
ABSTRACT
Se revisan los antecedentes históricos del conteo de reticulocitos como determinación indispensable en el laboratorio de hematología para la evaluación de la actividad eritropoyética durante la clasificación, diagnóstico y monitoreo de la respuesta terapéutica en distintos trastornos y situaciones clínicas, principalmente en casos de anemias. Se describe el tránsito del tradicional método de conteo de reticulocitos manual al método automatizado y la integración de los parámetros reticulocitarios al hemograma automatizado actual; además, se analizan las desventajas del método de recuento manual y las ventajas del método automatizado, así como los principios de detección en que se basa el conteo electrónico de reticulocitos. Con relación a los parámetros reticulocitarios, se describe su medición, cálculo y unidades de medida; también se resalta la importancia de la fracción de reticulocitos inmaduros y del contenido de hemoglobina reticulocitaria como variables de mayor uso clínico e investigativo en la evaluación de la respuesta medular ante diversos trastornos clínicos y protocolos terapéuticos. Por último, se alude a la necesidad del conocimiento y empleo de las variables reticulocitarias en la práctica clínica de rutina por parte de los clínicos y especialistas en hematología.
The historical background of reticulocyte count is reviewed as an essential determination in the laboratory of hematology for the evaluation of erythropoietic activity during classification, diagnosis and monitoring of therapeutic response of different conditions and clinical situations are also reviewed, especially in anemia The transition from traditional manual reticulocyte counting method to automated method and integration of the reticulocyte parameters to current automated complete blood count are described. The disadvantages of manual method and the advantages of automated methods are cited, as well as detection principles in which electronic reticulocyte count is based. Regarding reticulocyte parameters, measurement, calculation and units are described. The importance of immature reticulocyte fraction and reticulocyte hemoglobin content as variables most clinical and research use in evaluating bone marrow response to various clinical disorders and therapeutic protocols are highlighted. Finally, the need for knowledge and use of reticulocyte variables in routine clinical practice by clinicians and hematologist is referred.
Subject(s)
Humans , Male , Female , Reticulocyte Count/history , Reticulocyte Count/methods , Automation, Laboratory/methods , Electrical Equipment and SuppliesABSTRACT
Resumen: la incorporación de los autoanalizador de hematología al laboratorio clínico no solo mejoró la calidad de los resultados de los parámetros convencionales del hemograma sino que ha permitido,especialmente con aquellos de última generación, introducir nuevos parámetros de gran utilidad clínica. Uno de los nuevos parámetros es la hemoglobina reticulocitaria, la cual se vislumbra como una potente herramienta en el diagnóstico y el manejo de la eritropoyesis deficiente en hierro en sus diferentes manifestaciones, en particular la deficiencia absoluta de hierro, la deficiencia funcional de hierro y el secuestro del hierro. La hemoglobina reticulocitaria en todos los casos en donde hay eritropoyesis deficiente en hierro es el primer parámetro detectable en el hemograma y, a su vez, es el primero que se normaliza cuando la terapia administrada ha sido la adecuada; además, ha demostradoser costo eficiente, sobre todo por ser un parámetro del hemograma más que una prueba adicional. El único problema, hasta el momento, es que solo está disponible en algunos autoanalizadoresde hematología como los de las compañías Siemens y Sysmex, en sus modelos de cuarta generación, también conocidos como hemograma tipo VI o hemograma ampliado o extendido. Con el presente módulo se pretende presentar este nuevo parámetro que la comunidad médica debe incorporar como propio y los laboratorios clínicos deberían estar preparados para incorporarlo a sus portafolios de servicios, como una nueva herramienta complementaria en la prevención, la detección y el manejo de la eritropoyesis deficiente en hierro en sus diversas manifestaciones.
Abstract: the incorporation of hematology autoanalyzers in the clinical laboratory improved the quality of the results of conventional blood count (CBC) parameters. In addition, these machines, especially those of last generation, have allowed introducing new parameters of great clinical utility. One of these new parameters is the reticulocyte hemoglobin that is emerging as a powerful tool in the diagnosis and management of iron-deficient erythropoiesis. Also is useful in several of its forms, particularly in absolute iron deficiency, functional iron deficiency, and iron sequestration. The reticulocyte hemoglobin in all cases where there is iron-deficient erythropoiesis is the first parameter detectable in the CBC, in turn; it is the first that is normalized when the administered therapy has been adequate. It has also proven to be cost effective, especially for being a CBC parameter more than an additional test. The only problem so far is that it is only available in some hematology autoanalyzers as those of Siemens and Sysmex companies, in its fourth generation models, also known as type-VI CBC or expanded or extended CBC. With this module pretends to present a new parameter that the medical community should incorporate as own and the clinical laboratories should be prepared to include it into their service portfolios as a new complementary tool in the prevention, detection, and management of iron-deficient erythropoiesis in its various manifestations.
Subject(s)
Humans , Blood Cell Count , ErythropoiesisABSTRACT
A pesar del amplio uso del hierro endovenoso en hemodiálisis, resta aún identificar un índice adecuado para optimizar esta terapéutica en el largo plazo. Con ese objetivo, se diseñó un estudio prospectivo de cohorte, de larga duración, que consistió en un período basal (PB) y dos períodos experimentales: PI y PII. Se infundió hierro dextran de bajo peso molecular a 100, 150 y 200 mg/mes, respectivamente, durante 6 meses y al final de cada periodo se determinaron: saturación de transferrina (TSAT), ferritina (FERR), porcentaje de eritrocitos hipocrómicos (HYPO) y contenido de hemoglobina en reticulocitos (HCr). Durante el estudio la albúmina aumentó significativamente, pero la Hgb, la dosis de EPO y la proteína C-reactiva se mantuvieron sin cambios. Los cambios en HYPO y FERR fueron inespecíficos. Sólo TSAT (desde 21.4 ± 6 en PB a 34 ± 7.1% en PII, p = 0.01) y HCr (desde 27.5 ± 1.3 en PB a 29.3 ± 1.7 pg en PII, P = 0.045) respondieron específicamente, pero el porcentaje de aumento de TSAT fue de 65% (IC95% 22), y el de HCr sólo 6% (IC95% 2.3; p = 0.0002). Esta diferencia a favor de TSAT se observó en todos los pacientes. Los resultados sugieren la utilización de 200 mg/FeIV/mes y que, de los índices estudiados, TSAT sería el más adecuado para optimizar el uso a largo plazo del hierro endovenoso en hemodiálisis.
The usefulness of intravenous iron therapy in hemodialysis is evidence-based. However, controversy still arises about the most suitable iron marker to optimize this treatment in the long term. We aimed to determine the most suitable marker with a prospective, cohort study, designed to comprise a basal period (BP) and two consecutive experimental periods (PI, PII). Low molecular weight iron dextran was infused at 100, 150 and 200 mg/month respectively, on a biweekly basis, during 6 months. At the end of each period, the following were determined: transferrin saturation (TSAT), ferritin (FERR), percentage of hypochromic eritrocytes (HYPO) and haemoglobin content in reticulocytes (HCr). During the study, albumin increased significantly, whereas no significant changes in hemoglobin, EPO doses and C-reactive protein were observed. Changes in HYPO and FERR were unspecific. Only TSAT (from 21.4 ± 6 in PB to 34 ± 7.1% in PII, p < 0.01) and HCr (from 27.5 ± 1.3 in PB to 29.3 ± 1.7 pg in PII, P < 0.05 ) responded specifically to changes in Fe doses, but change of TSAT was 65% (CI 95% 22), whereas change of HCr was just 6% (CI 95% 2.3; p = 0.0002). The difference was observed in all patients. Results suggest that 200 mg/FeIV/month is effective and that, of the markers tested in this study, TSAT would be the most suitable one to the practicing nephrologist to optimize intravenous iron in the long term.
Subject(s)
Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Young Adult , Anemia, Iron-Deficiency/drug therapy , Iron-Dextran Complex/administration & dosage , Renal Dialysis/adverse effects , Transferrin/analysis , Anemia, Iron-Deficiency/blood , Biomarkers/blood , Dose-Response Relationship, Drug , Epidemiologic Methods , Hematinics/administration & dosage , Infusions, IntravenousABSTRACT
BACKGROUND: Iron deficiency anemia (IDA) is the most common anemia followed by anemia of chronic disease (ACD). Reticulocyte indices have been shown to be helpful indicators for detecting IDA. We investigated whether RBC and reticulocyte indices can be used to differentiate ACD from IDA. METHODS: A total of 85 women showing microcytic hypochromic anemia (38 IDA and 47 ACD cases) were enrolled. IDA was defined as those with ferritin level of 450 microg/dL. ACD was defined as ferritin level of > or =6 microg/dL, TIBC of or =24.6 pg could be used to differentiate ACD from IDA with 85.1% sensitivity and 81.6% specificity. CONCLUSIONS: The reticulocyte indices, especially CHr, are useful for the differential diagnosis of microcytic hypochromic anemias, ACD and IDA.
Subject(s)
Adult , Female , Humans , Anemia , Anemia, Hypochromic , Anemia, Iron-Deficiency , Blood Cell Count , Chronic Disease , Diagnosis, Differential , Erythrocyte Indices , Ferritins , Hemoglobins , Iron , Reticulocytes , ROC Curve , Sensitivity and SpecificityABSTRACT
PURPOSE: Early identification of iron deficiency in young children is essential to prevent damaging long-term consequences. It is often difficult for the pediatrician to know which indices should be used when diagnosing these conditions especially in hospitalized young children. This study investigated the clinical significances of reticulocyte hemoglobin content in young children with acute infection. METHODS: We studied 69 young children aged from 6 to 24 months admitted with acute infection in a single center. Venous blood was drawn to determine hemoglobin (Hb), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), hemoglobin content (CH), reticulocyte hemoglobin content (CHr), and red blood cell distribution width (RDW) using ADVIA 120 (Bayer Diagnostics, NY, USA). For evaluating iron status, iron, total iron binding capacity, ferritin and transferrin saturation (Tfsat) were determined. Iron deficiency was defined as Tfsat less than 20%, and iron deficiency anemia as Tfsat less than 20% and Hb level less than 11 g/dL. RESULTS: In all, 47 were iron deficient; 17 of these had iron deficiency anemia. CHr was the only significant predictor of iron deficiency (likelihood ratio test=71.25; odds ratio=0.67; P<0.05). Plasma ferritin level had no predictive value (P=0.519). Subjects with CHr less than 27.4 pg had lower Hb level, MCH, CH, Tfsat, and iron levels than those with CHr 27.4 pg or more (P<0.05 for all). CONCLUSION: CHr level was a sensitive screening tool and the strongest predictor of iron deficiency in hospitalized infants with acute infection; it was cost saving and avoiding additional sampling. However its reference range should be established.